| 2026-08-30in 5 d | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | PFEPfizer | Phase 3 | Multiple Myeloma | Recruiting |
| 2026-08-31in 6 d | Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) | 4568.TDaiichi Sankyo | Phase 3 | Gastroesophageal Cancer | Active, not recruiting |
| Aug 2026≤ 6 d | A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. | ABBVAbbVie | Phase 3 | Multiple Myeloma | Active, not recruiting |
| Aug 2026≤ 6 d | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | ABBVAbbVie | Phase 3 | Atopic Dermatitis | Recruiting |
| Aug 2026≤ 6 d | A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants | ABBVAbbVie | Phase 3 | Mid Face Volume Deficit | Active, not recruiting |
| Aug 2026≤ 6 d | A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease | ABBVAbbVie | Phase 3 | Dry Eye Disease | Active, not recruiting |
| Aug 2026≤ 6 d | To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis | AKBAAkebia Therapeutics | Phase 3 | Chronic Kidney Disease | Active, not recruiting |
| Aug 2026≤ 6 d | A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) | CINPHA.STCinclus Pharma Holding AB | Phase 3 | GERD (Gastroesophageal Reflux Disease) | Active, not recruiting |
| Aug 2026≤ 6 d | A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) | CYTKCytokinetics | Phase 3 | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | Active, not recruiting |
| Aug 2026≤ 6 d | PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301) | ENSCEnsysce Biosciences | Phase 3 | Postoperative Pain, Acute | Recruiting |
| Aug 2026≤ 6 d | Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice | HLNHALEON | Phase 3 | Dentin Hypersensitivity | Active, not recruiting |
| Aug 2026≤ 6 d | Study of VYD2311 for the Prevention of COVID-19 | IVVDInvivyd, Inc. | Phase 3 | COVID-19 | Active, not recruiting |
| Aug 2026≤ 6 d | Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine | IVVDInvivyd, Inc. | Phase 3 | COVID-19 | Recruiting |
| Aug 2026≤ 6 d | A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK | KODKodiak Sciences Inc | Phase 3 | Age-Related Macular Degeneration | Active, not recruiting |
| Aug 2026≤ 6 d | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | KPTIKaryopharm Therapeutics Inc | Phase 3 | Endometrial Cancer | Active, not recruiting |
| Aug 2026≤ 6 d | Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) | LLYEli Lilly and Company | Phase 3 | Type 2 Diabetes | Active, not recruiting |
| Aug 2026≤ 6 d | A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4) | MIRMMirum Pharmaceuticals, Inc. | Phase 3 | Chronic Hepatitis D Infection | Active, not recruiting |
| 2026-08-31in 6 d | A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease. | PFEPfizer | Phase 3 | Respiratory Syncytial Virus | Recruiting |
| Aug 2026≤ 6 d | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body | RCUSArcus Biosciences, Inc. | Phase 3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | Active, not recruiting |
| Aug 2026≤ 6 d | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | XENEXenon Pharmaceuticals Inc. | Phase 3 | Major Depressive Disorder | Recruiting |
| 2026-09-01in 7 d | Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years | ARDXArdelyx | Phase 3 | Irritable Bowel Syndrome With Constipation (IBS-C) | Active, not recruiting |
| 2026-09-01in 7 d | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | INCYIncyte Corporation | Phase 3 | Diffuse Large B-Cell Lymphoma | Active, not recruiting |
| 2026-09-05in 11 d | A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | HLUN-B.COH. Lundbeck A/S | Phase 3 | Chronic Migraine in Children | Recruiting |
| 2026-09-06in 12 d | A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65 | ALK-B.COALK-Abelló A/S | Phase 3 | Allergic Rhinoconjunctivitis, Allergic Rhinitis | Active, not recruiting |
| 2026-09-17in 23 d | An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant | VRTXVertex Pharmaceuticals Incorporated | Phase 3 | Type 1 Diabetes | Recruiting |
| 2026-09-21in 27 d | CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) | CRDLCardiol Therapeutics Inc. | Phase 3 | Recurrent Pericarditis | Recruiting |
| 2026-09-27in 33 d | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus | BIIBBiogen | Phase 3 | Systemic Lupus Erythematosus | Active, not recruiting |
| 2026-09-28in 34 d | An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN) | MLTXMoonLake Immunotherapeutics AG | Phase 3 | Hidradenitis Suppurativa | Active, not recruiting |
| 2026-09-28in 34 d | A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease | OCGNOcugen | Phase 2/3 | Stargardt Disease | Active, not recruiting |
| Sep 2026≤ 36 d | A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab | ABBVAbbVie | Phase 3 | Psoriatic Arthritis | Recruiting |
| Sep 2026≤ 36 d | Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder | ALKSAlkermes, Inc. | Phase 3 | Schizophrenia | Recruiting |
| Sep 2026≤ 36 d | C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV | AVIRAtea Pharmaceuticals, Inc. | Phase 3 | HEPATITIS C VIRUS CHRONIC INFECTION | Active, not recruiting |
| 2026-09-30in 36 d | A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | AZNAstraZeneca | Phase 3 | Lung Cancer | Active, not recruiting |
| 2026-09-30in 36 d | Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC | AZNAstraZeneca | Phase 3 | Hepatocellular Carcinoma | Active, not recruiting |
| 2026-09-30in 36 d | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | AZNAstraZeneca | Phase 3 | Lung Cancer | Recruiting |
| 2026-09-30in 36 d | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus | BIIBBiogen | Phase 3 | Systemic Lupus Erythematosus | Active, not recruiting |
| Sep 2026≤ 36 d | A Study to Investigate Stannous Fluoride Containing Toothpaste on Antibacterial Effects in the Different Regions of the Mouth | CLColgate Palmolive | Phase 3 | Gingivitis | Not yet recruiting |
| Sep 2026≤ 36 d | Comparative Efficacy of Different Dentin Occluding Toothpaste Technologies | CLColgate Palmolive | Phase 3 | Dentinal Sensitivity, Dentinal Hypersensitivity | Recruiting |
| Sep 2026≤ 36 d | Study of Bitopertin in Participants With EPP or XLP (APOLLO) | IRONDisc Medicine, Inc | Phase 3 | Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP) | Active, not recruiting |
| Sep 2026≤ 36 d | A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) | LLYEli Lilly and Company | Phase 3 | Perennial Allergic Rhinitis (PAR) | Active, not recruiting |
| Sep 2026≤ 36 d | AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) | RGNXREGENXBIO Inc. | Phase 2/3 | Duchenne Muscular Dystrophy | Active, not recruiting |
| Sep 2026≤ 36 d | Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) | SUPNSupernus Pharmaceuticals, Inc. | Phase 3 | Attention-Deficit/Hyperactivity Disorder | Active, not recruiting |
| Sep 2026≤ 36 d | Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) | VNDAVanda Pharmaceuticals | Phase 3 | Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm, Chronobiology Disorders | Active, not recruiting |
| 2026-10-01in 37 d | A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation | NVONovo Nordisk A/S | Phase 3 | Heart Failure | Active, not recruiting |
| 2026-10-05in 41 d | A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | SOBI.STSwedish Orphan Biovitrum | Phase 3 | Myelofibrosis | Active, not recruiting |
| 2026-10-06in 42 d | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis | BMYBristol-Myers Squibb | Phase 3 | Idiopathic Pulmonary Fibrosis | Active, not recruiting |
| 2026-10-07in 43 d | Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) | REGNRegeneron Pharmaceuticals | Phase 3 | Atopic Dermatitis | Active, not recruiting |
| 2026-10-09in 45 d | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) | INCYIncyte Corporation | Phase 3 | Hidradenitis Suppurativa | Active, not recruiting |
| 2026-10-09in 45 d | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) | INCYIncyte Corporation | Phase 3 | Hidradenitis Suppurativa | Active, not recruiting |
| 2026-10-12in 48 d | A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment | REGNRegeneron Pharmaceuticals | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | Active, not recruiting |
| 2026-10-14in 50 d | A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps | SNYSanofi | Phase 3 | Chronic Rhinosinusitis | Active, not recruiting |
| 2026-10-19in 55 d | A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) | BMYBristol-Myers Squibb | Phase 3 | Systemic Lupus Erythematosus | Active, not recruiting |
| 2026-10-19in 55 d | A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus | BMYBristol-Myers Squibb | Phase 3 | Systemic Lupus Erythematosus | Active, not recruiting |
| 2026-10-19in 55 d | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | INCYIncyte Corporation | Phase 3 | Prurigo Nodularis | Active, not recruiting |
| 2026-10-19in 55 d | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | INCYIncyte Corporation | Phase 3 | Prurigo Nodularis | Active, not recruiting |
| 2026-10-20in 56 d | A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | BIIBBiogen | Phase 2/3 | Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | Active, not recruiting |
| 2026-10-22in 58 d | A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State | AMGNAmgen | Phase 3 | Sjögren's Syndrome (SS) | Active, not recruiting |
| 2026-10-30in 66 d | A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy | VRTXVertex Pharmaceuticals Incorporated | Phase 3 | Cystic Fibrosis | Active, not recruiting |
| Oct 2026≤ 67 d | Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD | ABBVAbbVie | Phase 3 | Age-Related Macular Degeneration | Active, not recruiting |
| 2026-10-31in 67 d | A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | ANNXAnnexon, Inc. | Phase 3 | Geographic Atrophy | Active, not recruiting |
| 2026-10-31in 67 d | Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients | AZNAstraZeneca | Phase 3 | Breast Cancer | Active, not recruiting |
| Oct 2026≤ 67 d | Clinical Study to Evaluate Remineralization Using an in Situ Model. | CLColgate Palmolive | Phase 3 | Remineralization, Enamel Lesions, Enamel Subsurface Lesion | Not yet recruiting |
| Oct 2026≤ 67 d | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria | CLDXCelldex Therapeutics | Phase 3 | Chronic Spontaneous Urticaria | Active, not recruiting |
| Oct 2026≤ 67 d | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) | CLDXCelldex Therapeutics | Phase 3 | Chronic Spontaneous Urticaria | Active, not recruiting |
| Oct 2026≤ 67 d | A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) | LLYEli Lilly and Company | Phase 3 | Systemic Juvenile Idiopathic Arthritis | Active, not recruiting |
| Oct 2026≤ 67 d | Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) | LLYEli Lilly and Company | Phase 3 | Type 2 Diabetes | Active, not recruiting |
| Oct 2026≤ 67 d | Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) | MIRMMirum Pharmaceuticals, Inc. | Phase 3 | Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) | Active, not recruiting |
| Oct 2026≤ 67 d | Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects | OGNOrganon and Co | Phase 3 | Psoriasis | Active, not recruiting |
| 2026-10-31in 67 d | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | OLMAOlema Pharmaceuticals, Inc. | Phase 3 | Breast Cancer | Active, not recruiting |
| 2026-10-31in 67 d | A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) | SRPTSarepta Therapeutics, Inc. | Phase 3 | Duchenne Muscular Dystrophy | Active, not recruiting |
| 2026-10-31in 67 d | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) | TGTXTG Therapeutics, Inc. | Phase 3 | Multiple Sclerosis | Active, not recruiting |
| Oct 2026≤ 67 d | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) | XENEXenon Pharmaceuticals Inc. | Phase 3 | Epilepsy and Seizure Disorders | Recruiting |
| 2026-11-01in 68 d | A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder | BMYBristol-Myers Squibb | Phase 3 | Bipolar-I Disorder With Mania or Mania With Mixed Features | Recruiting |
| 2026-11-01in 68 d | Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab | SRRKScholar Rock, Inc. | Phase 3 | Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations, Anti-myostatin | Active, not recruiting |
| 2026-11-02in 69 d | A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus | AZNAstraZeneca | Phase 3 | Cutaneous Lupus Erythematosus | Active, not recruiting |
| 2026-11-02in 69 d | A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2) | BMYBristol-Myers Squibb | Phase 3 | Bipolar Disorder Type I With Mania or Mania With Mixed Features | Recruiting |
| 2026-11-06in 73 d | A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps | SNYSanofi | Phase 3 | Chronic Rhinosinusitis | Active, not recruiting |
| 2026-11-11in 78 d | Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | AZNAstraZeneca | Phase 3 | Breast Cancer; HER2-positive; Metastatic | Active, not recruiting |
| 2026-11-15in 82 d | Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes | ACHVAchieve Life Sciences | Phase 3 | Vaping Cessation | Not yet recruiting |
| 2026-11-18in 85 d | A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | BMYBristol-Myers Squibb | Phase 3 | Sjögren's Syndrome | Active, not recruiting |
| 2026-11-29in 96 d | A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | PFEPfizer | Phase 3 | Menstrual Migraine | Recruiting |
| Nov 2026≤ 97 d | A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series | 051910.KSLG Chem | Phase 2/3 | Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, Haemophilus Influenzae Type b | Recruiting |
| Nov 2026≤ 97 d | A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET | CAMX.STCamurus AB | Phase 3 | Gastro-enteropancreatic Neuroendocrine Tumor | Active, not recruiting |
| Nov 2026≤ 97 d | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | CGONCG Oncology, Inc. | Phase 3 | Bladder Cancer | Active, not recruiting |
| Nov 2026≤ 97 d | To Assess the Efficacy of Two Brushing Regimens: in the Reduction of Established Dental Plaque and Gingivitis. | CLColgate Palmolive | Phase 3 | Gingivitis | Active, not recruiting |
| Nov 2026≤ 97 d | Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | DBV.PADBV Technologies | Phase 3 | Allergy, Peanut Allergy | Active, not recruiting |
| Nov 2026≤ 97 d | Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | IMUXImmunic AG | Phase 3 | Multiple Sclerosis | Active, not recruiting |
| Nov 2026≤ 97 d | Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | IMUXImmunic AG | Phase 3 | Multiple Sclerosis | Active, not recruiting |
| Nov 2026≤ 97 d | A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight | LLYEli Lilly and Company | Phase 3 | Obstructive Sleep Apnea | Active, not recruiting |
| Nov 2026≤ 97 d | A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | LLYEli Lilly and Company | Phase 3 | Obesity | Active, not recruiting |
| Nov 2026≤ 97 d | A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | LLYEli Lilly and Company | Phase 3 | Type 1 Diabetes | Active, not recruiting |
| Nov 2026≤ 97 d | A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | LLYEli Lilly and Company | Phase 3 | Type 1 Diabetes | Active, not recruiting |
| 2026-11-30in 97 d | Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | RNACCartesian Therapeutics | Phase 3 | Myasthaenia Gravis | Recruiting |
| 2026-11-30in 97 d | Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan | SNYSanofi | Phase 3 | Immune Thrombocytopenia | Active, not recruiting |
| 2026-12-01in 98 d | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) | BIIBBiogen | Phase 3 | Antibody-mediated Rejection | Active, not recruiting |
| 2026-12-01in 98 d | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) | CMPXCompass Therapeutics | Phase 2/3 | Biliary Tract Cancer | Active, not recruiting |
| 2026-12-01in 98 d | A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD | SNYSanofi | Phase 3 | COPD | Active, not recruiting |
| 2026-12-01in 98 d | A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use | VNDAVanda Pharmaceuticals | Phase 3 | Obesity | Recruiting |
| 2026-12-02in 99 d | A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. | PFEPfizer | Phase 3 | Castration-Resistant Prostate Cancer | Recruiting |
| 2026-12-02in 99 d | A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | PFEPfizer | Phase 3 | Alopecia Areata | Active, not recruiting |
| 2026-12-04in 101 d | A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine | PFEPfizer | Phase 3 | Lyme Disease | Recruiting |
| 2026-12-14in 111 d | Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) | AMGNAmgen | Phase 3 | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | Active, not recruiting |
| 2026-12-14in 111 d | ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | NVONovo Nordisk A/S | Phase 3 | Cardiovascular Risk, Acute Myocardial Infarction (AMI) | Recruiting |
| 2026-12-15in 112 d | Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | EXELExelixis | Phase 3 | Non-Clear Cell Renal Cell Carcinoma | Active, not recruiting |
| 2026-12-15in 112 d | A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows | IPN.PAIpsen | Phase 3 | Moderate to Severe Glabellar Lines | Recruiting |
| 2026-12-15in 112 d | A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows | IPN.PAIpsen | Phase 3 | Moderate to Severe Glabellar Lines | Recruiting |
| 2026-12-17in 114 d | A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) | IPN.PAIpsen | Phase 3 | Primary Biliary Cholangitis | Active, not recruiting |
| 2026-12-26in 123 d | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | INCYIncyte Corporation | Phase 3 | Hidradenitis Suppurativa | Active, not recruiting |
| 2026-12-28in 125 d | A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | PFEPfizer | Phase 3 | Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Active, not recruiting |
| 2026-12-30in 127 d | Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | PFEPfizer | Phase 3 | Breast Cancer | Active, not recruiting |
| Dec 2026≤ 128 d | Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin | 068270.KSCelltrion | Phase 3 | Type 2 Diabetes | Recruiting |
| 2026-12-31in 128 d | Global Trial in APG2575 for Patients With CLL/SLL | AAPGAscentage Pharma Group Inc. | Phase 3 | Chronic Lymphocytic Leukemia | Recruiting |
| Dec 2026≤ 128 d | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | ABBVAbbVie | Phase 2/3 | Age-Related Macular Degeneration | Active, not recruiting |
| Dec 2026≤ 128 d | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | ABBVAbbVie | Phase 3 | Hidradenitis Suppurativa | Active, not recruiting |
| Dec 2026≤ 128 d | A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma | ALDXAldeyra Therapeutics, Inc. | Phase 3 | Primary Vitreoretinal Lymphoma | Recruiting |
| 2026-12-31in 128 d | An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) | ANNXAnnexon, Inc. | Phase 3 | Guillain-Barre Syndrome | Recruiting |
| Dec 2026≤ 128 d | C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV | AVIRAtea Pharmaceuticals, Inc. | Phase 3 | HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C | Active, not recruiting |
| Dec 2026≤ 128 d | Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol | AXSMAxsome Therapeutics, Inc. | Phase 3 | Binge-Eating Disorder | Recruiting |
| Dec 2026≤ 128 d | Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) | AXSMAxsome Therapeutics, Inc. | Phase 3 | Excessive Sleepiness, Shift-work Disorder | Recruiting |
| 2026-12-31in 128 d | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab | AZNAstraZeneca | Phase 3 | Cancer | Enrolling by invitation |
| Dec 2026≤ 128 d | Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) | DMACDiaMedica Therapeutics Inc | Phase 2/3 | Acute Stroke, Ischemic Stroke, Stroke | Recruiting |
| Dec 2026≤ 128 d | Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | GILDGilead Sciences | Phase 3 | Breast Cancer | Active, not recruiting |
| Dec 2026≤ 128 d | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | GNLXGenelux Corporation | Phase 3 | Ovarian Cancer | Recruiting |
| 2026-12-31in 128 d | An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) | INSMInsmed Incorporated | Phase 2/3 | Pulmonary Arterial Hypertension | Active, not recruiting |
| Dec 2026≤ 128 d | A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) | IONSIonis Pharmaceuticals, Inc. | Phase 3 | Hereditary Angioedema | Active, not recruiting |
| Dec 2026≤ 128 d | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | KPTIKaryopharm Therapeutics Inc | Phase 2/3 | Diffuse Large B-Cell Lymphoma | Active, not recruiting |
| Dec 2026≤ 128 d | A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa | KRYSKrystal Biotech, Inc. | Phase 3 | Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa | Recruiting |
| Dec 2026≤ 128 d | Safety and Efficacy of VDPHL01 in Males With AGA | MANEVeradermics, Inc. | Phase 3 | Androgenetic Alopecia, AGA, Male Pattern Baldness | Active, not recruiting |
| Dec 2026≤ 128 d | A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | MDGLMadrigal Pharmaceuticals, Inc. | Phase 3 | MASH / Nonalcoholic Steatohepatitis | Active, not recruiting |
| Dec 2026≤ 128 d | A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE) | MDWDMediWound Ltd | Phase 3 | Venous Leg Ulcer (VLU) | Recruiting |
| 2026-12-31in 128 d | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | PFEPfizer | Phase 3 | Lung Cancer | Active, not recruiting |
| Dec 2026≤ 128 d | A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine | PRAXPraxis Precision Medicines | Phase 3 | Developmental and Epileptic Encephalopathy 1 | Active, not recruiting |
| Dec 2026≤ 128 d | A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety | PRAXPraxis Precision Medicines | Phase 3 | Epilepsy and Seizure Disorders | Recruiting |
| Dec 2026≤ 128 d | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | UTHRUnited Therapeutics | Phase 3 | Hypertension | Enrolling by invitation |
| 2026-12-31in 128 d | A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection | VIRVir Biotechnology, Inc. | Phase 3 | Viral Hepatitis | Active, not recruiting |
| Dec 2026≤ 128 d | A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide | VIRVir Biotechnology, Inc. | Phase 3 | Viral Hepatitis | Active, not recruiting |
| Dec 2026≤ 128 d | Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder | VNDAVanda Pharmaceuticals | Phase 3 | Social Anxiety Disorder (SAD) | Active, not recruiting |
| 2027-01-04in 132 d | A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH | AZNAstraZeneca | Phase 3 | Heterozygous Familial Hypercholesterolaemia | Active, not recruiting |
| 2027-01-06in 134 d | Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | AZNAstraZeneca | Phase 3 | Systemic Sclerosis | Active, not recruiting |
| 2027-01-07in 135 d | Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease | SNYSanofi | Phase 3 | Sickle Cell Disease | Recruiting |
| 2027-01-08in 136 d | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | OCULOcular Therapeutix, Inc. | Phase 3 | Age-Related Macular Degeneration | Active, not recruiting |
| 2027-01-11in 139 d | A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event | AZNAstraZeneca | Phase 3 | Cardiovascular Disease | Active, not recruiting |
| 2027-01-13in 141 d | A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab | AZNAstraZeneca | Phase 3 | Chronic Rhinosinusitis | Active, not recruiting |
| 2027-01-15in 143 d | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | IDYAIDEAYA Biosciences | Phase 2/3 | Metastatic Uveal Melanoma | Active, not recruiting |
| 2027-01-15in 143 d | Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | MLTXMoonLake Immunotherapeutics AG | Phase 3 | Psoriatic Arthritis | Recruiting |
| 2027-01-18in 146 d | Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. | PFEPfizer | Phase 3 | Lower Respiratory Tract Illness | Active, not recruiting |
| 2027-01-21in 149 d | Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | AMGNAmgen | Phase 3 | Obesity | Active, not recruiting |
| 2027-01-21in 149 d | Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | AMGNAmgen | Phase 3 | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | Active, not recruiting |
| 2027-01-21in 149 d | Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | TGTXTG Therapeutics, Inc. | Phase 3 | Multiple Sclerosis | Recruiting |
| 2027-01-25in 153 d | A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | NVONovo Nordisk A/S | Phase 3 | Type 1 Diabetes | Recruiting |
| 2027-01-25in 153 d | A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF | PFEPfizer | Phase 3 | Respiratory Syncytial Virus | Recruiting |
| 2027-01-25in 153 d | Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) | VRTXVertex Pharmaceuticals Incorporated | Phase 3 | Diabetic Peripheral Neuropathic Pain | Active, not recruiting |
| 2027-01-28in 156 d | A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults | MRNAModernaTX, Inc. | Phase 3 | Influenza | Active, not recruiting |
| 2027-01-29in 157 d | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | PFESeagen, a wholly owned subsidiary of Pfizer | Phase 3 | Urothelial Carcinoma | Active, not recruiting |
| Jan 2027≤ 159 d | Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis | ABBVAbbVie | Phase 3 | Atopic Dermatitis | Active, not recruiting |
| Jan 2027≤ 159 d | Study of COYA 302 for the Treatment of ALS | COYACoya Therapeutics | Phase 2/3 | Amyotrophic Lateral Sclerosis (ALS) | Recruiting |
| Jan 2027≤ 159 d | Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 | PCVXVaxcyte, Inc. | Phase 3 | Pneumococcal Disease | Active, not recruiting |
| Jan 2027≤ 159 d | Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures | PRAXPraxis Precision Medicines | Phase 3 | Epilepsy and Seizure Disorders | Active, not recruiting |
| 2027-01-31in 159 d | Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome | QNRXQuoin Pharmaceuticals | Phase 2/3 | Netherton Syndrome | Recruiting |
| Jan 2027≤ 159 d | Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta | RAREUltragenyx Pharmaceutical Inc | Phase 3 | Osteogenesis Imperfecta | Active, not recruiting |
| Jan 2027≤ 159 d | An Open-Label Study of Azetukalner in Major Depressive Disorder | XENEXenon Pharmaceuticals Inc. | Phase 3 | Major Depressive Disorder | Enrolling by invitation |
| 2027-02-04in 163 d | Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug | MLTXMoonLake Immunotherapeutics AG | Phase 3 | Psoriatic Arthritis | Active, not recruiting |
| 2027-02-12in 171 d | A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa | OCGNOcugen | Phase 3 | Retinitis Pigmentosa | Active, not recruiting |
| 2027-02-15in 174 d | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis | MRNAModernaTX, Inc. | Phase 3 | Acute Gastroenteritis, Norovirus Acute Gastroenteritis | Active, not recruiting |
| 2027-02-17in 176 d | An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps | SNYSanofi | Phase 3 | Chronic Rhinosinusitis | Active, not recruiting |
| 2027-02-18in 177 d | Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) | AZNAstraZeneca | Phase 3 | Chronic Kidney Disease | Active, not recruiting |
| 2027-02-20in 179 d | REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults | REGNRegeneron Pharmaceuticals | Phase 3 | Venous Thromboembolism (VTE) | Recruiting |
| 2027-02-22in 181 d | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T) | AZNAstraZeneca | Phase 3 | Cancer | Active, not recruiting |
| 2027-02-22in 181 d | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia | AZNAstraZeneca | Phase 2/3 | Dyslipidaemia | Active, not recruiting |
| 2027-02-23in 182 d | Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | AZNAstraZeneca | Phase 3 | Lupus Nephritis | Active, not recruiting |
| 2027-02-26in 185 d | A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults | ARDXArdelyx | Phase 3 | Chronic Idiopathic Constipation (CIC) | Recruiting |
| Feb 2027≤ 187 d | A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis | 068270.KSCelltrion | Phase 3 | Multiple Sclerosis | Recruiting |
| Feb 2027≤ 187 d | A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer | 068270.KSCelltrion | Phase 3 | Non Squamous Non Small Cell Lung Cancer | Active, not recruiting |
| Feb 2027≤ 187 d | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | GILDGilead Sciences | Phase 3 | Breast Cancer | Active, not recruiting |
| 2027-02-28in 187 d | Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep Apnea | INSPInspire Medical Systems, Inc. | Phase 3 | Obstructive Sleep Apnea | Active, not recruiting |
| Feb 2027≤ 187 d | A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE | KODKodiak Sciences Inc | Phase 3 | Macular Edema Secondary to Inflammation | Recruiting |
| Feb 2027≤ 187 d | A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | LLYEli Lilly and Company | Phase 3 | Obesity | Recruiting |
| 2027-02-28in 187 d | Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy | REGNRegeneron Pharmaceuticals | Phase 3 | Allergic Conjunctivitis | Recruiting |
| 2027-03-01in 188 d | A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | NVONovo Nordisk A/S | Phase 3 | Obesity | Active, not recruiting |
| 2027-03-11in 198 d | A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | BMYBristol-Myers Squibb | Phase 3 | Renal Cell Carcinoma | Active, not recruiting |
| 2027-03-13in 200 d | A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) | RYTMRhythm Pharmaceuticals, Inc. | Phase 3 | Obesity | Recruiting |
| 2027-03-17in 204 d | Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | PFEPfizer | Phase 3 | Ulcerative Colitis | Active, not recruiting |
| 2027-03-22in 209 d | A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | REGNRegeneron Pharmaceuticals | Phase 3 | Melanoma | Recruiting |
| 2027-03-25in 212 d | A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia | SNYSanofi | Phase 3 | Hemophilia | Active, not recruiting |
| 2027-03-31in 218 d | A Study of Olverembatinib in SDH-deficient GIST. | AAPGAscentage Pharma Group Inc. | Phase 3 | GIST | Recruiting |
| Mar 2027≤ 218 d | A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. | ABBVAbbVie | Phase 3 | Bipolar Disorder | Recruiting |
| Mar 2027≤ 218 d | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | ABBVAbbVie | Phase 3 | Systemic Lupus Erythematosus | Active, not recruiting |
| Mar 2027≤ 218 d | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | ABBVAbbVie | Phase 3 | Crohn's Disease | Active, not recruiting |
| 2027-03-31in 218 d | Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma | HURATuHURA Biosciences, Inc. | Phase 2/3 | Advanced Or Metastatic Merkel Cell Carcinoma | Recruiting |
| Mar 2027≤ 218 d | CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) | IONSIonis Pharmaceuticals, Inc. | Phase 3 | Severe Hypertriglyceridemia | Active, not recruiting |
| Mar 2027≤ 218 d | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | MDGLMadrigal Pharmaceuticals, Inc. | Phase 3 | Non-Alcoholic Fatty Liver Disease | Active, not recruiting |
| Mar 2027≤ 218 d | A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy | OCULOcular Therapeutix, Inc. | Phase 3 | Non-Proliferative Diabetic Retinopathy | Recruiting |
| Mar 2027≤ 218 d | A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation | ONCBeOne Medicines | Phase 3 | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma | Active, not recruiting |
| Mar 2027≤ 218 d | A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age | PCVXVaxcyte, Inc. | Phase 3 | Pneumococcal Disease | Active, not recruiting |
| Mar 2027≤ 218 d | Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination | PCVXVaxcyte, Inc. | Phase 3 | Pneumococcal Disease | Active, not recruiting |
| 2027-03-31in 218 d | A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo | PFEPfizer | Phase 3 | Vitiligo | Active, not recruiting |
| Mar 2027≤ 218 d | Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa | SOBI.STSwedish Orphan Biovitrum | Phase 3 | Hemophilia A | Recruiting |
| Mar 2027≤ 218 d | A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome | STOKStoke Therapeutics, Inc | Phase 3 | Dravet Syndrome | Recruiting |
| Mar 2027≤ 218 d | A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer | URGNUroGen Pharma Ltd. | Phase 3 | Urothelial Carcinoma | Recruiting |
| 2027-04-05in 223 d | A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | SNYSanofi | Phase 3 | Plasma Cell Myeloma | Active, not recruiting |
